Program
ASKC202
A development code. Also written as “ASKC202+ Limertinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Beijing Aosaikang Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical | 33 open or running | phase 3since Jul 31, 2025 | Mar 23, 2022 | Dec 2026phase 1 · NCT05306132 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 23, 2022First study: phase 1 study in Advanced Solid TumorFirst studyNCT05306132 · 150 planned · China
- Jul 31, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531 · 286 planned · China
- Oct 20, 2026Phase 3 study in EGFR Activating MutationNCT07897188 · 425 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in Advanced Solid TumorNCT05306132
- Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07109531
- Dec 30, 2030Primary completion: phase 3 study in EGFR Activating MutationNCT07897188
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07897188EGFR Activating Mutation · China | 3 | Not yet recruiting | Dec 30, 2030 | 425 |
| NCT07109531Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Oct 31, 2027 | 286 |
| NCT05306132Advanced Solid Tumor · China | 1 | Recruiting | Dec 2026 | 150 |
How it is read
Names in the registry
- “ASKC202”, 2 entries
- “ASKC202+ Limertinib”, 1 entry
Codes read as this program: ASKC202.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.